This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes	α -Glucosidase	<p>A study in rats identified triazole-based inhibitors of α-glucosidase that could help treat type 2 diabetes. In rats, 50 mg/kg of two of the inhibitors significantly reduced glucose uptake from maltose compared with no treatment ($p < 0.05$). Next steps include further optimization of the inhibitors.</p> <p>Precose acarbose, an oral α-glucosidase inhibitor from Bayer AG, is marketed to treat type 2 diabetes.</p> <p>Voglibose is an α-glucosidase inhibitor from Takeda Pharmaceutical Co. Ltd. marketed for the same indication.</p> <p>SciBX 3(10); doi:10.1038/scibx.2010.309 Published online March 11, 2010</p>	<p>Patent pending for use in multiple indications including obesity and diabetes; available for licensing from the Federal University of Rio de Janeiro Innovation Agency</p>	<p>Ferreira, S.B. <i>et al. J. Med. Chem.</i>; published online Feb. 19, 2010; doi:10.1021/jm901265h</p> <p>Contact: Vitor F. Ferreira, Fluminense Federal University, Niteri, Rio de Janeiro, Brazil e-mail: cegvito@vm.uff.br</p>